Beyond antipsychotics: a twenty-first century update for preclinical development of schizophrenia therapeutics.
Journal
Translational psychiatry
ISSN: 2158-3188
Titre abrégé: Transl Psychiatry
Pays: United States
ID NLM: 101562664
Informations de publication
Date de publication:
07 04 2022
07 04 2022
Historique:
received:
16
12
2021
accepted:
15
03
2022
revised:
02
03
2022
entrez:
8
4
2022
pubmed:
9
4
2022
medline:
12
4
2022
Statut:
epublish
Résumé
Despite 50+ years of drug discovery, current antipsychotics have limited efficacy against negative and cognitive symptoms of schizophrenia, and are ineffective-with the exception of clozapine-against any symptom domain for patients who are treatment resistant. Novel therapeutics with diverse non-dopamine D
Identifiants
pubmed: 35393394
doi: 10.1038/s41398-022-01904-2
pii: 10.1038/s41398-022-01904-2
pmc: PMC8991275
doi:
Substances chimiques
Antipsychotic Agents
0
Clozapine
J60AR2IKIC
Dopamine
VTD58H1Z2X
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
147Informations de copyright
© 2022. The Author(s).
Références
Moreno-Küstner B, Martín C, Pastor L. Prevalence of psychotic disorders and its association with methodological issues. A systematic review and meta-analyses. PLOS ONE. 2018;13:e0195687–e0195687.
pubmed: 29649252
pmcid: 5896987
doi: 10.1371/journal.pone.0195687
Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: Version III-The final common pathway. Schizophr Bull. 2009;35:549–62.
pubmed: 19325164
pmcid: 2669582
doi: 10.1093/schbul/sbp006
Kambeitz J, Abi-Dargham A, Kapur S, Howes OD. Alterations in cortical and extrastriatal subcortical dopamine function in schizophrenia: systematic review and meta-analysis of imaging studies. Br J Psychiatry. 2014;204:420–29.
pubmed: 25029687
doi: 10.1192/bjp.bp.113.132308
López-Muñoz F, Alamo C, Cuenca E, Shen WW, Clervoy P, Rubio G. History of the discovery and clinical introduction of chlorpromazine. Ann Clin Psychiatry J Am Acad Clin Psychiatr. 2005;17:113–35.
doi: 10.1080/10401230591002002
Nucifora FC, Woznica E, Lee BJ, Cascella N, Sawa A. Treatment resistant schizophrenia: clinical, biological, and therapeutic perspectives. Neurobiol Dis. 2019;131:104257.
pubmed: 30170114
doi: 10.1016/j.nbd.2018.08.016
Girgis RR, Zoghbi AW, Javitt DC, Lieberman JA. The past and future of novel, non-dopamine-2 receptor therapeutics for schizophrenia: a critical and comprehensive review. J Psychiatr Res. 2019;108:57–83.
pubmed: 30055853
doi: 10.1016/j.jpsychires.2018.07.006
Reichenberg A, Feo C, Prestia D, Bowie CR, Patterson TL, Harvey PD. The course and correlates of everyday functioning in schizophrenia. Schizophr Res Cogn. 2014;1:e47–52.
pubmed: 25045625
doi: 10.1016/j.scog.2014.03.001
Milev P, Ho B-C, Arndt S, Andreasen NC. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am J Psychiatry. 2005;162:495–506.
pubmed: 15741466
doi: 10.1176/appi.ajp.162.3.495
McCutcheon RA, Krystal JH, Howes OD. Dopamine and glutamate in schizophrenia: biology, symptoms and treatment. World Psychiatry. 2020;19:15–33.
pubmed: 31922684
pmcid: 6953551
doi: 10.1002/wps.20693
Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson ML. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu Rev Pharmacol Toxicol. 2001;41:237–60.
Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry. 2011;70:663–71.
pubmed: 21641581
pmcid: 4071300
doi: 10.1016/j.biopsych.2011.04.013
Howes OD, Kapur S. A neurobiological hypothesis for the classification of schizophrenia: type a (hyperdopaminergic) and type B (normodopaminergic). Br J Psychiatry. 2014;205:1–3.
pubmed: 24986384
doi: 10.1192/bjp.bp.113.138578
Hauser TA, Kucinski A, Jordan KG, Gatto GJ, Wersinger SR, Hesse RA, et al. TC-5619: An alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia. Biochem Pharmacol. 2009;78:803–12.
pubmed: 19482012
pmcid: 3005247
doi: 10.1016/j.bcp.2009.05.030
Walling D, Marder SR, Kane J, Fleischhacker WW, Keefe RSE, Hosford DA, et al. Phase 2 trial of an alpha-7 nicotinic receptor agonist (TC-5619) in negative and cognitive symptoms of schizophrenia. Schizophr Bull. 2016;42:335–43.
pubmed: 26071208
doi: 10.1093/schbul/sbv072
Kumari S, Malik M, Florival C, Manalai P, Sonje S. An assessment of five (PANSS, SAPS, SANS, NSA-16, CGI-SCH) commonly used symptoms rating scales in schizophrenia and comparison to newer scales (CAINS, BNSS). J Addict Res Ther. 2017;8:324.
pubmed: 29430333
pmcid: 5805140
doi: 10.4172/2155-6105.1000324
Keefe RSE, Buchanan RW, Marder SR, Schooler NR, Dugar A, Zivkov M, et al. Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? Schizophr Bull. 2013;39:417–35.
pubmed: 22114098
doi: 10.1093/schbul/sbr153
Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, et al. How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat Rev Drug Discov. 2010;9:203–14.
pubmed: 20168317
doi: 10.1038/nrd3078
Walling DP, Banerjee A, Dawra V, Boyer S, Schmidt CJ, DeMartinis N. Phosphodiesterase 10A inhibitor monotherapy is not an effective treatment of acute schizophrenia. J Clin Psychopharmacol. 2019;39:575–82.
pubmed: 31688451
doi: 10.1097/JCP.0000000000001128
Macek TA, McCue M, Dong X, Hanson E, Goldsmith P, Affinito J, et al. A phase 2, randomized, placebo-controlled study of the efficacy and safety of TAK-063 in subjects with an acute exacerbation of schizophrenia. Schizophr Res. 2019;204:289–94.
pubmed: 30190165
doi: 10.1016/j.schres.2018.08.028
Bugarski-Kirola D, Blaettler T, Arango C, Fleischhacker WW, Garibaldi G, Wang A, et al. Bitopertin in negative symptoms of schizophrenia—results from the phase III flashlyte and daylyte studies. Biol Psychiatry. 2017;82:8–16.
pubmed: 28117049
doi: 10.1016/j.biopsych.2016.11.014
Neurocrine Biosciences, Inc. Neurocrine Biosciences announces top-line results from phase II INTERACT study evaluating luvadaxistat (NBI-1065844) for the treatment of negative symptoms and cognitive impairment associated with schizophrenia (CIAS). SAN DIEGO: Neurocrine Biosciences, Inc; 2021.
Adams DH, Kinon BJ, Baygani S, Millen BA, Velona I, Kollack-Walker S, et al. A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia. BMC Psychiatry. 2013;13:143.
pubmed: 23694720
pmcid: 3666887
doi: 10.1186/1471-244X-13-143
Downing AM, Kinon BJ, Millen BA, Zhang L, Liu L, Morozova MA, et al. A double-blind, placebo-controlled comparator study of LY2140023 monohydrate in patients with schizophrenia. BMC Psychiatry. 2014;14:351.
pubmed: 25539791
pmcid: 4276262
doi: 10.1186/s12888-014-0351-3
Brannan S. 32.2 Two global phase iii trials of encenicline for cognitive impairment in chronic schizophrenia patients: red flags and lessons learned. Schizophrenia Bull. 2019;45:S141–S142.
doi: 10.1093/schbul/sbz022.133
Huang M, Felix AR, Flood DG, Bhuvaneswaran C, Hilt D, Koenig G, et al. The novel α7 nicotinic acetylcholine receptor agonist EVP-6124 enhances dopamine, acetylcholine, and glutamate efflux in rat cortex and nucleus accumbens. Psychopharmacol (Berl). 2014;231:4541–51.
doi: 10.1007/s00213-014-3596-0
Arai AC, Kessler M. Pharmacology of ampakine modulators: from AMPA receptors to synapses and behavior. Curr Drug Targets. 2007;8:583–602.
pubmed: 17504103
doi: 10.2174/138945007780618490
Goff DC, Lamberti JS, Leon AC, Green MF, Miller AL, Patel J, et al. A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia. Neuropsychopharmacol Publ Am Coll Neuropsychopharmacol. 2008;33:465–72.
doi: 10.1038/sj.npp.1301444
Ranganathan M, DeMartinis N, Huguenel B, Gaudreault F, Bednar MM, Shaffer CL, et al. Attenuation of ketamine-induced impairment in verbal learning and memory in healthy volunteers by the AMPA receptor potentiator PF-04958242. Mol Psychiatry. 2017;22:1633–40.
pubmed: 28242871
doi: 10.1038/mp.2017.6
Stahl SM. Mechanism of action of ketamine. CNS Spectr. 2013;18:171–4.
pubmed: 23866089
doi: 10.1017/S109285291300045X
Mouchlianitis E, Bloomfield MA, Law V, Beck K, Selvaraj S, Rasquinha N, et al. Treatment-resistant schizophrenia patients show elevated anterior cingulate cortex glutamate compared to treatment-responsive. Schizophr Bull. 2016;42:744–52.
pubmed: 26683625
doi: 10.1093/schbul/sbv151
Yun S, Yang B, Martin MM, Yeh N-H, Contractor A, Parker JG. Modulating D1 rather than D2 receptor-expressing spiny-projection neurons corresponds to optimal antipsychotic effect. 2021. https://www.biorxiv.org/content/10.1101/2021.08.03.454992v1 https://doi.org/10.1101/2021.08.03.454992 .
Koblan KS, Kent J, Hopkins SC, Krystal JH, Cheng H, Goldman R, et al. A non-D2-receptor-binding drug for the treatment of schizophrenia. N Engl J Med. 2020;382:1497–1506.
pubmed: 32294346
doi: 10.1056/NEJMoa1911772
Heffernan MLR, Herman LW, Brown S, Jones PG, Shao L, Hewitt MC, et al. Ulotaront: A TAAR1 agonist for the treatment of schizophrenia. ACS Med Chem Lett. 2022;13:92–8.
pubmed: 35047111
doi: 10.1021/acsmedchemlett.1c00527
Demjaha A, Murray RM, McGuire PK, Kapur S, Howes OD. Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. Am J Psychiatry. 2012;169:1203–10.
pubmed: 23034655
doi: 10.1176/appi.ajp.2012.12010144
Dedic N, Jones PG, Hopkins SC, Lew R, Shao L, Campbell JE, et al. SEP-363856, a novel psychotropic agent with a unique, non-D2 receptor mechanism of action. J Pharmacol Exp Ther. 2019;371:1–14.
pubmed: 31371483
doi: 10.1124/jpet.119.260281
Begni V, Sanson A, Luoni A, Sensini F, Grayson B, Munni S, et al. Towards novel treatments for schizophrenia: molecular and behavioural signatures of the psychotropic agent SEP-363856. Int J Mol Sci. 2021;22:4119.
pubmed: 33923479
pmcid: 8073823
doi: 10.3390/ijms22084119
Brannan SK, Sawchak S, Miller AC, Lieberman JA, Paul SM, Breier A. Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia. N Engl J Med. 2021;384:717–26.
pubmed: 33626254
pmcid: 7610870
doi: 10.1056/NEJMoa2017015
Bodick NC, Offen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol. 1997;54:465–73.
pubmed: 9109749
doi: 10.1001/archneur.1997.00550160091022
Shekhar A, Potter WZ, Lightfoot J, Lienemann J, Dubé S, Mallinckrodt C, et al. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry. 2008;165:1033–39.
pubmed: 18593778
doi: 10.1176/appi.ajp.2008.06091591
Woolley ML, Carter HJ, Gartlon JE, Watson JM, Dawson LA. Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated in muscarinic M1 receptor knockout mice. Eur J Pharmacol. 2009;603:147–9.
pubmed: 19111716
doi: 10.1016/j.ejphar.2008.12.020
Thorn CA, Moon J, Bourbonais CA, Harms J, Edgerton JR, Stark E, et al. Striatal, hippocampal, and cortical networks are differentially responsive to the M4- and M1-muscarinic acetylcholine receptor mediated effects of xanomeline. ACS Chem Neurosci. 2019;10:1753–64.
pubmed: 30480428
doi: 10.1021/acschemneuro.8b00625
Krystal JH, Kane JM, Correll CU, Walling DP, Leoni M, Duvvuri S, et al. P493. CVL-231 as a Novel Positive Allosteric Modulator of Cholinergic M4 Receptors for the Treatment of Schizophrenia: Results From an Early Proof-Of-Concept Study in Patients With Schizophrenia. ACNP 60th Annual Meeting: Poster Abstracts P276 – P550. Neuropsychopharmacol. 2021;46:218–368.
Brown AJH, Bradley SJ, Marshall FH, Brown GA, Bennett KA, Brown J, et al. From structure to clinic: Design of a muscarinic M1 receptor agonist with potential to treatment of Alzheimer’s disease. Cell. 2021;184:5886–5901.e22.
pubmed: 34822784
doi: 10.1016/j.cell.2021.11.001
Gould RW, Grannan MD, Gunter BW, Ball J, Bubser M, Bridges TM, et al. Cognitive enhancement and antipsychotic-like activity following repeated dosing with the selective M4 PAM VU0467154. Neuropharmacology. 2018;128:492–502.
pubmed: 28729220
doi: 10.1016/j.neuropharm.2017.07.013
Jones CA, Watson DJG, Fone KCF. Animal models of schizophrenia. Br J Pharmacol. 2011;164:1162–194.
pubmed: 21449915
pmcid: 3229756
doi: 10.1111/j.1476-5381.2011.01386.x
Gainetdinov RR, Mohn AR, Caron MG. Genetic animal models: focus on schizophrenia. Trends Neurosci. 2001;24:527–33.
pubmed: 11506886
doi: 10.1016/S0166-2236(00)01886-5
Winship IR, Dursun SM, Baker GB, Balista PA, Kandratavicius L, Maia-de-Oliveira JP, et al. An overview of animal models related to schizophrenia. Can J Psychiatry. 2019;64:5–17.
pubmed: 29742910
doi: 10.1177/0706743718773728
Zheutlin AB, Dennis J, Karlsson Linnér R, Moscati, A, Restrepo N, Straub P, et al. Penetrance and pleiotropy of polygenic risk scores for schizophrenia in 106,160 patients across four health care systems. Am J Psychiatry. 2019;176:846–55.
Lipska BK, Weinberger DR. To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology. 2000;23:223–39.
pubmed: 10942847
doi: 10.1016/S0893-133X(00)00137-8
Bell DS. The experimental reproduction of amphetamine psychosis. Arch Gen Psychiatry. 1973;29:35–40.
pubmed: 4711131
doi: 10.1001/archpsyc.1973.04200010020003
Connell PH. Amphetamine psychosis. Br Med J. 1957;1:582.
pmcid: 1974659
doi: 10.1136/bmj.1.5018.582
Seeman P, Lee T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science. 1975;188:1217–19.
pubmed: 1145194
doi: 10.1126/science.1145194
Powell CM, Miyakawa T. Schizophrenia-relevant behavioral testing in rodent models: a uniquely human disorder? Biol Psychiatry. 2006;59:1198–207.
pubmed: 16797265
pmcid: 3928106
doi: 10.1016/j.biopsych.2006.05.008
Arguello PA, Gogos JA. Modeling madness in mice: one piece at a time. Neuron. 2006;52:179–96.
pubmed: 17015235
doi: 10.1016/j.neuron.2006.09.023
Mclean JR, Parker RB, Coughenour LL. Effect of antipsychotic and other classes of drugs on spontaneous locomotor activity and neurotoxicity in mice. Pharmacol Biochem Behav. 1978;8:97–9.
pubmed: 24225
doi: 10.1016/0091-3057(78)90130-2
Schmack K, Bosc M, Ott T, Sturgill JF, Kepecs A. Striatal dopamine mediates hallucination-like perception in mice. Science. 2021;372:eabf4740.
Kesby JP, Eyles DW, McGrath JJ, Scott JG. Dopamine, psychosis and schizophrenia: the widening gap between basic and clinical neuroscience. Transl Psychiatry. 2018;8:1–12.
doi: 10.1038/s41398-017-0071-9
Luo M, Fee MS, Katz LC. Encoding pheromonal signals in the accessory olfactory bulb of behaving mice. Science. 2003;299:1196–201.
pubmed: 12595684
doi: 10.1126/science.1082133
Moberg PJ, Agrin R, Gur RE, Gur RC, Turetsky BI, Doty RL. Olfactory dysfunction in schizophrenia: a qualitative and quantitative review. Neuropsychopharmacology. 1999;21:325–40.
pubmed: 10457530
doi: 10.1016/S0893-133X(99)00019-6
Shamsi S, Lau A, Lencz T, Burdick KE, DeRosse P, Brenner R, et al. Cognitive and symptomatic predictors of functional disability in schizophrenia. Schizophr Res. 2011;126:257–64.
pubmed: 20828991
doi: 10.1016/j.schres.2010.08.007
Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry. 1996;153:321–30.
pubmed: 8610818
doi: 10.1176/ajp.153.3.321
Harvey PD, Howanitz E, Parrella M, White L, Davidson M, Mohs RC, et al. Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites. Am J Psychiatry. 1998;155:1080–6.
pubmed: 9699697
doi: 10.1176/ajp.155.8.1080
Buchanan RW, Keefe RSE, Lieberman JA, Barch DM, Csernansky JG, Goff DC, et al. A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biol Psychiatry. 2011;69:442–49.
pubmed: 21145041
doi: 10.1016/j.biopsych.2010.09.052
Callahan PM, Terry AV, Tehim A. Effects of the nicotinic α7 receptor partial agonist GTS-21 on NMDA-glutamatergic receptor related deficits in sensorimotor gating and recognition memory in rats. Psychopharmacol (Berl). 2014;231:3695–3706.
doi: 10.1007/s00213-014-3509-2
Damgaard T, Larsen DB, Hansen SL, Grayson B, Neill JC, Plath N. Positive modulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors reverses sub-chronic PCP-induced deficits in the novel object recognition task in rats. Behav Brain Res. 2010;207:144–150.
pubmed: 19822174
doi: 10.1016/j.bbr.2009.09.048
Freedman R, Olincy A, Buchanan RW, Harris JG, Gold JM, Johnson L, et al. Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry. 2008;165:1040–47.
pubmed: 18381905
pmcid: 3746983
doi: 10.1176/appi.ajp.2008.07071135
Freudenreich O, Henderson DC, Macklin EA, Evins AE, Fan X, Cather C, et al. Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebo-controlled pilot trial. J Clin Psychiatry. 2009;70:1674–80.
pubmed: 19689921
pmcid: 5038350
doi: 10.4088/JCP.08m04683
Friedman JI, Carpenter D, Lu J, Fan J, Tang CY, White L, et al. A pilot study of adjunctive atomoxetine treatment to second-generation antipsychotics for cognitive impairment in schizophrenia. J Clin Psychopharmacol. 2008;28:59–63.
pubmed: 18204342
doi: 10.1097/jcp.0b013e318161318f
Karamihalev S, Prickaerts J, van Goethem NP. Donepezil and the alpha-7 agonist PHA 568487, but not risperidone, ameliorate spatial memory deficits in a subchronic MK-801 mouse model of cognitive impairment in schizophrenia. Behav Brain Res. 2014;272:248–51.
pubmed: 25036424
doi: 10.1016/j.bbr.2014.07.017
Keefe RSE, Malhotra AK, Meltzer HY, Kane JM, Buchanan RW, Murthy A, et al. Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacol Publ Am Coll Neuropsychopharmacol. 2008;33:1217–28.
doi: 10.1038/sj.npp.1301499
Li Y-X, Ye Z-H, Chen T, Jia X-F, He L. The effects of donepezil on phencyclidine-induced cognitive deficits in a mouse model of schizophrenia. Pharmacol Biochem Behav. 2018;175:69–76.
pubmed: 30218672
doi: 10.1016/j.pbb.2018.09.006
Potasiewicz A, Hołuj M, Kos T, Popik P, Arias HR, Nikiforuk A. 3-Furan-2-yl-N-p-tolyl-acrylamide, a positive allosteric modulator of the α7 nicotinic receptor, reverses schizophrenia-like cognitive and social deficits in rats. Neuropharmacology. 2017;113:188–97.
pubmed: 27717880
doi: 10.1016/j.neuropharm.2016.10.002
Rajagopal L, Huang M, Michael E, Kwon S, Meltzer HY. TPA-023 attenuates subchronic phencyclidine-induced declarative and reversal learning deficits via GABA A receptor agonist mechanism: possible therapeutic target for cognitive deficit in schizophrenia. Neuropsychopharmacology. 2018;43:2468–77.
pubmed: 30093697
pmcid: 6180114
doi: 10.1038/s41386-018-0160-3
Redrobe JP, Bull S, Plath N. Translational aspects of the novel object recognition task in rats abstinent following sub-chronic treatment with phencyclidine (PCP): effects of modafinil and relevance to cognitive deficits in schizophrenia. Front Psychiatry. 2010;1:146.
Wilson CA, Terry AV. Variable maternal stress in rats alters locomotor activity, social behavior, and recognition memory in the adult offspring. Pharmacol Biochem Behav. 2013;104:47–61.
pubmed: 23287801
doi: 10.1016/j.pbb.2012.12.015
Bussey TJ, Holmes A, Lyon L, Mar AC, McAllister KAL, Nithianantharajah J, et al. New translational assays for preclinical modelling of cognition in schizophrenia: the touchscreen testing method for mice and rats. Neuropharmacology. 2012;62:1191–203.
pubmed: 21530550
doi: 10.1016/j.neuropharm.2011.04.011
Nithianantharajah J, McKechanie AG, Stewart TJ, Johnstone M, Blackwood DH, St Clair D, et al. Bridging the translational divide: identical cognitive touchscreen testing in mice and humans carrying mutations in a disease-relevant homologous gene. Sci Rep. 2015;5:14613.
pubmed: 26423861
pmcid: 4589696
doi: 10.1038/srep14613
Nithianantharajah J, Komiyama NH, McKechanie A, Johnstone M, Blackwood DH, Clair DS, et al. Synaptic scaffold evolution generated components of vertebrate cognitive complexity. Nat Neurosci. 2013;16:16–24.
pubmed: 23201973
doi: 10.1038/nn.3276
Kirov G, Pocklington AJ, Holmans P, Ivanov D, Ikeda M, Ruderfer D, et al. De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia. Mol Psychiatry. 2012;17:142–53.
pubmed: 22083728
doi: 10.1038/mp.2011.154
Kim M, Kwak C, Yu N-K, Kaang B-K. Optimization of the touchscreen paired-associate learning (PAL) task for mice and its dorsal hippocampal dependency. Anim Cells Syst. 2016;20:229–36.
doi: 10.1080/19768354.2016.1221855
Heath CJ, Phillips BU, Bussey TJ, Saksida LM. Measuring motivation and reward-related decision making in the rodent operant touchscreen system. Curr Protoc Neurosci. 2016;74:8.34.1–8.34.20.
doi: 10.1002/0471142301.ns0834s74
Wahl D, Coogan SC, Solon-Biet SM, de Cabo R, Haran JB, Raubenheimer D, et al. Cognitive and behavioral evaluation of nutritional interventions in rodent models of brain aging and dementia. Clin Interv Aging. 2017;12:1419–28.
pubmed: 28932108
pmcid: 5598548
doi: 10.2147/CIA.S145247
Sarpal DK, Argyelan M, Robinson DG, Szeszko PR, Karlsgodt KH, John M, et al. Baseline striatal functional connectivity as a predictor of response to antipsychotic drug treatment. Am J Psychiatry. 2016;173:69–77.
pubmed: 26315980
doi: 10.1176/appi.ajp.2015.14121571
Li A, Zalesky A, Yue W, Howes O, Yan H, Liu Y, et al. A neuroimaging biomarker for striatal dysfunction in schizophrenia. Nat Med. 2020;26:558–65.
pubmed: 32251404
doi: 10.1038/s41591-020-0793-8
Kambeitz J, Kambeitz-Ilankovic L, Leucht S, Wood S, Davatzikos C, Malchow B, et al. Detecting neuroimaging biomarkers for schizophrenia: a meta-analysis of multivariate pattern recognition studies. Neuropsychopharmacol Publ Am Coll Neuropsychopharmacol. 2015;40:1742–51.
doi: 10.1038/npp.2015.22
Gillespie AL, Samanaite R, Mill J, Egerton A, MacCabe JH. Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? a systematic review. BMC Psychiatry. 2017;17:12–12.
pubmed: 28086761
pmcid: 5237235
doi: 10.1186/s12888-016-1177-y
Kim E, Howes OD, Veronese M, Beck K, Seo S, Park JW, et al. Presynaptic dopamine capacity in patients with treatment-resistant schizophrenia taking clozapine: an [(18)F]DOPA PET Study. Neuropsychopharmacol Publ Am Coll Neuropsychopharmacol. 2017;42:941–50.
doi: 10.1038/npp.2016.258
Jauhar S, Veronese M, Nour MM, Rogdaki M, Hathway P, Natesan S, et al. The effects of antipsychotic treatment on presynaptic dopamine synthesis capacity in first-episode psychosis: a positron emission tomography study. Biol Psychiatry. 2019;85:79–87.
pubmed: 30122287
doi: 10.1016/j.biopsych.2018.07.003
Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJM, Birnbaum ML, et al. Treatment resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry. 2017;174:216–29.
pubmed: 27919182
doi: 10.1176/appi.ajp.2016.16050503
Demjaha A, Lappin JM, Stahl D, Patel MX, MacCabe JH, Howes OD, et al. Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors. Psychol Med. 2017;47:1981–89.
pubmed: 28395674
doi: 10.1017/S0033291717000435
Lally J, Ajnakina O, Forti MD, Trotta A, Demjaha A, Kolliakou A, et al. Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses. Psychol Med. 2016;46:3231–40.
pubmed: 27605254
doi: 10.1017/S0033291716002014
Lieberman JA, Kane JM, Alvir J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacol Berl. 1987;91:415–33.
doi: 10.1007/BF00216006
Carlsson A, Lindqvist M, Magnusson TOR. 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature. 1957;180:1200.
pubmed: 13483658
doi: 10.1038/1801200a0
Carlsson A, Lindqvist M. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol (Copenh). 1963;20:140–44.
doi: 10.1111/j.1600-0773.1963.tb01730.x
Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science. 1976;192:481–3.
pubmed: 3854
doi: 10.1126/science.3854
Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature. 1976;261:717.
pubmed: 945467
doi: 10.1038/261717a0
Cumming P, Abi-Dargham A, Gründer G. Molecular imaging of schizophrenia: neurochemical findings in a heterogeneous and evolving disorder. Behav Brain Res. 2021;398:113004.
pubmed: 33197459
doi: 10.1016/j.bbr.2020.113004
Howes OD, Kambeitz J, Kim E, Stahl D, Slifstein M, Abi-Dargham A, et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry. 2012;69:776–86.
pubmed: 22474070
pmcid: 3730746
doi: 10.1001/archgenpsychiatry.2012.169
Miyake N, Thompson J, Skinbjerg M, Abi-Dargham A. Presynaptic dopamine in schizophrenia. CNS Neurosci Ther. 2011;17:104–9.
pubmed: 21199451
doi: 10.1111/j.1755-5949.2010.00230.x
Cumming P, Deep P, Rousset O, Evans A, Gjedde A. On the rate of decarboxylation of dopa to dopamine in living mammalian brain. Ann N Acad Sci. 1997;835:274–308.
doi: 10.1111/j.1749-6632.1997.tb48637.x
Meiser J, Weindl D, Hiller K. Complexity of dopamine metabolism. Cell Commun Signal. 2013;11:34.
pubmed: 23683503
pmcid: 3693914
doi: 10.1186/1478-811X-11-34
Fusar-Poli P, Meyer-Lindenberg A. Striatal presynaptic dopamine in schizophrenia, Part II: meta-analysis of [18F/11C]-DOPA PET studies. Schizophr Bull. 2013;39:33–42.
pubmed: 22282454
doi: 10.1093/schbul/sbr180
Jauhar S, Veronese M, Nour MM, Rogdaki M, Hathway P, Turkheimer FE, et al. Determinants of treatment response in first-episode psychosis: an 18 F-DOPA PET study. Mol Psychiatry. 2019;24:1502–12.
pubmed: 29679071
doi: 10.1038/s41380-018-0042-4
Kim S, Jung WH, Howes OD, Veronese M, Turkheimer FE, Lee Y-S, et al. Frontostriatal functional connectivity and striatal dopamine synthesis capacity in schizophrenia in terms of antipsychotic responsiveness: an [18F]DOPA PET and fMRI study. Psychol Med. 2019;49:2533–42.
pubmed: 30460891
doi: 10.1017/S0033291718003471
Lieberman JA, Safferman AZ, Pollack S, Szymanski S, Johns C, Howard A, et al. Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry. 1994;151:1744–52.
pubmed: 7977880
doi: 10.1176/ajp.151.12.1744
Bleuler E. Dementia Praecox Oder Gruppe der Schizophrenien. Leipzig, Germany: Franz Deuticke; 1911.
McGuire PK, Frith CD. Disordered functional connectivity in schizophrenia. Psychol Med. 1996;26:663–67.
pubmed: 8817700
doi: 10.1017/S0033291700037673
Wernicke C. Grundriss der Psychiatrie in klinischen Vorlesungen. Leipzig, Germany: Georg Thieme; 1906.
Gur RE, Gur RC. Functional magnetic resonance imaging in schizophrenia. Dialogues Clin Neurosci. 2010;12:333–43.
pubmed: 20954429
pmcid: 3181978
doi: 10.31887/DCNS.2010.12.3/rgur
Hoffman RE, Fernandez T, Pittman B, Hampson M. Elevated functional connectivity along a corticostriatal loop and the mechanism of auditory/verbal hallucinations in patients with schizophrenia. Biol Psychiatry. 2011;69:407–14.
pubmed: 21145042
doi: 10.1016/j.biopsych.2010.09.050
Fornito A, Harrison BJ, Goodby E, Dean A, Ooi C, Nathan PJ, et al. Functional dysconnectivity of corticostriatal circuitry as a risk phenotype for psychosis. JAMA Psychiatry. 2013;70:1143–51.
pubmed: 24005188
doi: 10.1001/jamapsychiatry.2013.1976
McCutcheon R, Beck K, Jauhar S, Howes OD. Defining the locus of dopaminergic dysfunction in schizophrenia: a meta-analysis and test of the mesolimbic hypothesis. Schizophr Bull. 2018;44:1301–11.
pubmed: 29301039
doi: 10.1093/schbul/sbx180
Sarpal DK, Robinson DG, Lencz T, Argyelan M, Ikuta T, Karlsgodt K, et al. Antipsychotic treatment and functional connectivity of the striatum in first-episode schizophrenia. JAMA Psychiatry. 2015;72:5–13.
pubmed: 25372846
pmcid: 4286512
doi: 10.1001/jamapsychiatry.2014.1734
White TP, Wigton R, Joyce DW, Collier T, Fornito A, Shergill SS. Dysfunctional striatal systems in treatment-resistant schizophrenia. Neuropsychopharmacology. 2016;41:1274–85.
pubmed: 26346637
doi: 10.1038/npp.2015.277
Potkin SG, Kane JM, Correll CU, Lindenmayer J-P, Agid O, Marder SR, et al. The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research. NPJ Schizophr. 2020;6:1–10.
pubmed: 31911624
pmcid: 6946650
doi: 10.1038/s41537-019-0090-z
Thompson JL, Urban N, Slifstein M, Xu X, Kegeles LS, Girgis RR, et al. Striatal dopamine release in schizophrenia comorbid with substance dependence. Mol Psychiatry. 2013;18:909–15.
pubmed: 22869037
doi: 10.1038/mp.2012.109
Egerton A, Murphy A, Donocik J, Anton A, Barker, GJ, Collier T, et al. Dopamine and glutamate in antipsychotic-responsive compared with antipsychotic-nonresponsive psychosis: a multicenter positron emission tomography and magnetic resonance spectroscopy study (STRATA). Schizophr Bull. 2021. https://doi.org/10.1093/schbul/sbaa128 .
Demjaha A, Egerton A, Murray RM, Kapur S, Howes OD, Stone JM, et al. Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function. Biol Psychiatry. 2014;75:e11–13.
pubmed: 23890739
doi: 10.1016/j.biopsych.2013.06.011
Egerton A, Brugger S, Raffin M, Barker GJ, Lythgoe DJ, McGuire PK, et al. Anterior cingulate glutamate levels related to clinical status following treatment in first-episode schizophrenia. Neuropsychopharmacol Publ Am Coll Neuropsychopharmacol. 2012;37:2515–21.
doi: 10.1038/npp.2012.113
Goldstein ME, Anderson VM, Pillai A, Kydd RR, Russell BR. Glutamatergic neurometabolites in clozapine-responsive and -resistant schizophrenia. Int J Neuropsychopharmacol. 2015;18:pyu117.
Tarumi R, Tsugawa S, Noda Y, Plitman E, Honda S, Matsushita K, et al. Levels of glutamatergic neurometabolites in patients with severe treatment-resistant schizophrenia: a proton magnetic resonance spectroscopy study. Neuropsychopharmacology. 2020;45:632–40.
pubmed: 31842203
doi: 10.1038/s41386-019-0589-z
Marsman A, van den Heuvel MP, Klomp DWJ, Kahn RS, Luijten PR, Hulshoff Pol HE. Glutamate in schizophrenia: a focused review and meta-analysis of
pubmed: 21746807
doi: 10.1093/schbul/sbr069
Kegeles LS, Mao X, Stanford AD, Girgis R, Ojeil N, Xu X, et al. Elevated prefrontal cortex γ-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy. Arch Gen Psychiatry. 2012;69:449–59.
pubmed: 22213769
doi: 10.1001/archgenpsychiatry.2011.1519
Gleich T, Deserno L, Lorenz RC, Boehme R, Pankow A, Buchert R, et al. Prefrontal and striatal glutamate differently relate to striatal dopamine: potential regulatory mechanisms of striatal presynaptic dopamine function? J Neurosci. 2015;35:9615–21.
pubmed: 26134644
pmcid: 6605144
doi: 10.1523/JNEUROSCI.0329-15.2015
Jauhar S, McCutcheon R, Borgan F, Veronese M, Nour M, Pepper F, et al. The relationship between cortical glutamate and striatal dopamine in first-episode psychosis: a cross-sectional multimodal PET and magnetic resonance spectroscopy imaging study. Lancet Psychiatry. 2018;5:816–23.
pubmed: 30236864
pmcid: 6162342
doi: 10.1016/S2215-0366(18)30268-2
Meltzer HY. Treatment of the neuroleptic-nonresponsive schizophrenic patient. Schizophr Bull. 1992;18:515–42.
pubmed: 1357741
doi: 10.1093/schbul/18.3.515
Correll CU, Koblan KS, Hopkins SC, Li Y, Dworak H, Goldman, R, et al. Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study. NPJ Schizophr. 2021;7:1–9.
Sekar S, Grandjean J, Garnell JF, Willems R, Duytschaever H, Seramani S, et al. Neuro-metabolite profiles of rodent models of psychiatric dysfunctions characterised by MR spectroscopy. Neuropharmacology. 2019;146:109–116.
pubmed: 30472272
doi: 10.1016/j.neuropharm.2018.11.021
Zerbi V, Pagani M, Markicevic M, Matteoli M, Pozzi D, Fagiolini M, et al. Brain mapping across 16 autism mouse models reveals a spectrum of functional connectivity subtypes. Mol Psychiatry. 2021;26:7610–7620.
Kokkinou, M, Irvine, EE, Bonsall, DR, Natesan, S, Wells, LA, Smith, M, et al. Reproducing the dopamine pathophysiology of schizophrenia and approaches to ameliorate it: a translational imaging study with ketamine. Mol Psychiatry. 2020:1–15. https://doi.org/10.1038/s41380-020-0740-6 .
Bifone A, Gozzi A. Neuromapping techniques in drug discovery: pharmacological MRI for the assessment of novel antipsychotics. Expert Opin Drug Discov. 2012;7:1071–82.
pubmed: 22971143
doi: 10.1517/17460441.2012.724057
Petty A, Cui X, Ali A, Du Z, Srivastav S, Kesby JP, et al. Positive symptom phenotypes appear progressively in “EDiPS”, a new animal model of the schizophrenia prodrome. Sci Rep. 2021;11:4294.
pubmed: 33619296
pmcid: 7900200
doi: 10.1038/s41598-021-83681-4
DeFronzo RA, Ferrannini E, Groop L, Henry RR, Herman WH, Holst JJ, et al. Type 2 diabetes mellitus. Nat Rev Dis Prim. 2015;1:1–22.
Fragomeni SM, Sciallis A, Jeruss JS. Molecular subtypes and local-regional control of breast cancer. Surg Oncol Clin N Am. 2018;27:95–120.
pubmed: 29132568
pmcid: 5715810
doi: 10.1016/j.soc.2017.08.005
Katsarou A, Gudbjörnsdottir S, Rawshani A, Dabelea D, Bonifacio E, Anderson BJ, et al. Type 1 diabetes mellitus. Nat Rev Dis Prim. 2017;3:1–17.
Balsters JH, Zerbi V, Sallet J, Wenderoth N, Mars RB. Primate homologs of mouse cortico-striatal circuits. eLife. 2020;9:e53680.
pubmed: 32298231
pmcid: 7162658
doi: 10.7554/eLife.53680
Murray EA, Wise SP, Graham KS. The Evolution of Memory Systems: Ancestors, Anatomy, and Adaptations. Oxford, United Kingdom: Oxford University Press; 2016.
Pauli WM, O’Reilly RC, Yarkoni T, Wager TD. Regional specialization within the human striatum for diverse psychological functions. Proc Natl Acad Sci USA. 2016;113:1907–12.
pubmed: 26831091
pmcid: 4763751
doi: 10.1073/pnas.1507610113